Satellos Shares Early Adult Data for Duchenne Pill Ahead of Key Pediatric Readout

Satellos Bioscience has shared early clinical data from its adult Phase 1b trial of SAT-3247, an oral small molecule therapy for Duchenne muscular dystrophy (DMD). The trial showed promising functional improvements in grip strength and lung function in adults, with a near-doubling of grip strength and a 5.8% increase in predicted forced vital capacity after 28 days of treatment. These results were presented at the World Muscle Society Congress in 2025 and followed patients aged 20–27 years. Safety and tolerability were favorable, with no drug-related moderate or severe adverse events. The company is now advancing SAT-3247 into Phase 2 trials (BASECAMP in pediatric ambulatory DMD patients and TRAILHEAD in adults) while preparing for key pediatric data readouts later in 2026. FDA has granted Fast Track designation for SAT-3247 in DMD, underscoring its potential as a disease-modifying, dystrophin-independent oral approach.